Pfizer to close Mumbai manufacturing facility

By Zachary Brennan

- Last updated on GMT

Related tags India Andhra pradesh Maharashtra

Pfizer to close Mumbai manufacturing facility
With no active production at the plant since 2013, the company said it would shutter its Mumbai, India-based facility in mid-September, according to a Bombay Stock Exchange filing. 

The decision to close the Plant is based on an assessment of its long term viability and its ability to achieve the needed production​,” Pfizer said. “There has practically been no production activity at this plant since 2013, and the closure will not impact the supply of any of the Company's medicines to patients​.”

All of Pfizers' employees at the 50-year-old plant were offered a voluntary retirement scheme last year, and 132 out of 212 took the option. The company said the remaining workers continue to receive full wages despite the plant’s inactivity.

The closure comes as Pfizer’s recent acquisition of Hospira brings along with it an injectables plant in the Andhra Pradesh region of India​, which earlier this month got the go-ahead from the FDA to begin commercial production.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Webinars